Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors

Trial Profile

Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adrenocortical carcinoma; Paraganglioma; Penile cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Testicular cancer; Thymoma; Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 15 Aug 2016 Planned primary completion date changed from 1 Sep 2019 to 1 Aug 2019.
    • 05 Jul 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top